Novo Nordisk R&D

Since Novo Nordisk was founded more than 90 years ago, we have been changing diabetes. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done. 


The exciting potential of stem cell research

Mads Krogsgaard Thomsen, CSO of Novo Nordisk, considers the potential of stem cell-based therapies to cure type 1 diabetes and other chronic diseases

Read Mads’ perspective

Increased commitment to stem cell-based therapies

Head of Global Drug Discovery Marcus Schindler and Head of diabetes and stem cell research Jacob Sten Petersen shares insights into increased commitment to stem cell-based therapies.

Lotte Bjerre Knudsen, Scientific Vice President

Mother of molecules

Scientific Vice President Lotte Bjerre Knudsen talks about her experiences of taking an underdog molecule to a treatment for millions of people with diabetes and obesity

Listen to the podcast

The pursuit of oral insulin

Chief Science Officer Mads Krogsgaard Thomsen reflects on the past, present and future of insulin in a tablet.

Read the article

SIMONE K NIELSEN & HANNE BODENHOFF are working  in R&D at Novo Nordisk

Career in R&D

Looking for a job in Research and Development. Find more about a life-changing career in R&D with Novo Nordisk here




Novo Nordisk Partnerships

Partnering for innovation

We believe that partnerships are key to fostering innovation.

Our approach to innovation partnering

Partnering with patients

We are guided by the principle that a patient centered approach to our business must be informed by input from patients and win-win partnerships. Therefore, we work in partnership with a network called the Disease Experience Expert Panels (DEEPs).

Read about the DEEPs